Indomethacin News and Research

RSS

Implementation of quality improvement intervention reduces medication use in premature babies: Study

A new study by Pediatrix Medical Group researchers has found that the implementation of a quality improvement intervention significantly reduces the use of a large number of medications in premature babies across a broad neonatal intensive care network.

3 May 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

Targeting Wnt/beta-catenin pathway may prevent growth and development of AML: Study

About 40 percent of children and up to 70 percent of adults in remission from acute myelogenous leukemia will have a relapse. In recent years, doctors have come to believe that this is due to leukemia stem cells, endlessly replicating cancer cells that generate the immature blood cells characteristic of leukemia and are resistant to typical cancer treatments.

26 Mar 2010

FDA approves APP Pharmaceuticals' Indomethacin for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.

23 Mar 2010

Bedford Laboratories launches Indomethacin for Injection

Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., a provider of select specialty injectables, is pleased to announce the addition of Indomethacin for Injection to its existing product line. This product is AP rated and is equivalent to Indocin® by Lundbeck, Inc. Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.

17 Feb 2010

Study: EP4 agonist may reduce gastric bleeding and inflammation

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.

19 Nov 2009

Experimental study shows beneficial effects of Vardenafil on NSAID-induced gastric ulcer

Indomethacin has been proved by epidemiological and experimental studies to be closely associated with peptic ulcer development. Vardenafil is a potent phosphodiesterase 5 inhibitor and its effects on the gastric mucosa havenot been reported.

19 Nov 2009

Studies provide clues to how Alzheimer’s disease develops and may be treated

The anti-inflammatory drug indomethacin could hold promise as a treatment for Alzheimer's disease, says a Saint Louis University doctor and researcher.

12 Jul 2009

Salad herb shows potential gastric anti-ulcer activity

Gastric ulcer is an illness that affects a considerable number of people worldwide. Although the introduction of proton-pump inhibitors to the classic anti-ulcer therapy has revolutionized treatment of peptic ulcers and other gastrointestinal disorders, there is still no complete cure for this disease.

7 May 2009

Ibuprofen linked to lower risk of Alzheimer's

Long-term use of ibuprofen and other drugs commonly used for aches and pains was associated with a lower risk of Alzheimer's disease, according to a study published in the May 6, 2008, issue of Neurology, the medical journal of the American Academy of Neurology. Previous studies have shown conflicting results, but this is the longest study of its kind.

5 May 2008

Indomethacin a common drug for stopping preterm labor may be harmful for babies

A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue publishedthis monthin American Journal of Obstetrics and Gynecology.

21 Nov 2007

Indomethacin drug for stopping preterm labor may be harmful for babies

A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue published today in American Journal of Obstetrics and Gynecology.

2 Nov 2007

The future of Alzheimer's disease research

Imagine the day when a routine visit to the family doctor includes a simple blood test to predict the risk for developing Alzheimer's disease (AD).

26 Jul 2007

Celecoxib offers promise for premature babies

Scientists have found evidence that the cox-2 inhibitor celecoxib, a common pain reliever used to treat arthritis, may offer a new way to reduce the risk of the most common cause of brain damage in babies born prematurely.

18 May 2007

Lifestyle decisions that may stave off onset of cancer

Personal choices, such as smoking and consumption of fatty foods, have long been linked to increased cancer risk. During recent years, scientists have been seeking to isolate a variety of lifestyle decisions that may stave off the onset of cancer or even reduce tumor formation in their early stages.

14 Nov 2006

Doctors warned that commonly used painkillers linked to increased risk of heart attacks

Doctors in the UK are being warned that commonly used painkillers such as ibuprofen can increase the risk of heart attacks if taken over long periods.

25 Oct 2006

AUA podium session on stone disease

2-phase randomized crossover study on a constant diet with calcium carbonate supplementation at 250 mg 4 times daily.

13 Jun 2006

Common painkillers could up chance of heart failure in seniors

New research has revealed that commonly used over-the-counter painkillers, such as ibuprofen, are linked with a 30% increased risk of first hospital admission for heart failure.

22 May 2006

Economic benefit of federally finded clinical trials exceeds $15 billion

A comprehensive review of all phase III clinical trials supported by one Federal agency finds that, estimated conservatively, the economic benefit in the United States from just eight of these trials exceeded $15 billion over the course of 10 years. The study also found that new discoveries from the trials were responsible for an estimated additional 470,000 healthy years of life. The clinical trials were sponsored by the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS).

28 Apr 2006